Table 1 The demographic and clinical characteristics of participants
Parameters | HC (n = 22) | CHB (n = 58) | CHC (n = 31) |
|---|---|---|---|
Age (years) | 42 (22–74) | 48 (25–76) | 54 (34–74) |
Gender: Female/male | 6/16 | 17/41 | 9/22 |
ALT (U/L) | 27 (13–38) | 125 (13–2463)* | 57 (13–201)* |
AST (U/L) | 25 (10–36) | 106 (21–1932)* | 67 (16–173)* |
HCV RNA level (Log10 IU/ml) | NA | NA | 6.42 (3.69–8.60)* |
HBV DNA level (Log10 IU/ml) | NA | 7.26 (5.03–9.98)* | NA |
WBC (×109/L) | 5.57 (4.3–9.7) | 7.26 (4.60–12.5)* | 7.13 (4.8–12.3)* |
Lymphocytes (×109/L) | 1.70 (1.02–2.7) | 2.14 (1.36–3.12) | 1.92 (1.45–2.48) |
HBsAg (IU/ml) | NA | 29.63 (2.97–306.68)* | NA |
HBsAb (mIU/ml) | NA | 1.12 (0–391.73)* | NA |
HBeAg (S/CO) | NA | 2.38 (0.03–540.84)* | NA |
HBeAb (S/CO) | NA | 1.36 (0.02–24.57)* | NA |
HBcAb (S/CO) | NA | 1.04 (0.03–19.17)* | NA |
HCVAb (S/CO) | NA | NA | 7.28 (1.09–34.6)* |
HBeAg (+/−) | NA | 36/22 | NA |
Disease duration (month) | NA | 100.8 (14.4–324) | 12 (7–36) |